SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:1472 8206 OR L773:0767 3981 "

Sökning: L773:1472 8206 OR L773:0767 3981

  • Resultat 11-20 av 28
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
11.
  • Mihara, K, et al. (författare)
  • Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19
  • 1999
  • Ingår i: Fundamental & Clinical Pharmacology. - 0767-3981 .- 1472-8206. ; 13:6, s. 671-675
  • Tidskriftsartikel (refereegranskat)abstract
    • The purpose of the study was to determine the enantiomer pharmacokinetics of omeprazole and 5-hydroxy-omeprazole before and after administration of the antimalarial artemisinin to confirm artemisinin's ability to induce CYP2C19. Nine healthy male Vietnamese subjects were given a single 20 mg dose of omeprazole orally 1 week before (day -7) artemisinin administration. Artemisinin was then given orally (500 mg) for 7 days (days 1-7). On days 1 and 7, a single 20 mg dose of omeprazole was coadministered with artemisinin. After a washout period of 6 days, a single 20 mg dose of omeprazole was again administered together with a single 500 mg of artemisinin (day 14). Stereoselective pharmacokinetics of omeprazole and 5-hydroxyomeprazole was determined on days of omeprazole administration. Seven days of artemisinin administration significantly decreased the AUC of both omeprazole enantiomers (day 7), compared with day 1 (P < 0.001). All values were normalized after the washout period. Artemisinin increased the AUC ratio of R-5-hydroxyomeprazole/R-omeprazole significantly (P < 0.01) on day 7. The AUC ratio of omeprazole sulphone/S-omeprazole did not differ between study days. Artemisinin decreased the AUC of S-omeprazole to the same extent as that of R-omeprazole in extensive CYP2C19 metabolizers, suggesting that artemisinin induces a different enzyme in addition to CYP2C19. These results support and strengthen earlier findings that artemisinin induces CYP2C19 as well as at least one enzyme other than CYP3A4. 
  •  
12.
  •  
13.
  • Alfredsson, Joakim, et al. (författare)
  • Management of acute coronary syndromes from a gender perspective
  • 2010
  • Ingår i: FUNDAMENTAL and CLINICAL PHARMACOLOGY. - : Blackwell Publishing Ltd.. - 0767-3981. ; 24:6, s. 719-728
  • Forskningsöversikt (refereegranskat)abstract
    • Acute Coronary Syndromes are the most frequent manifestations of coronary heart disease (CHD). Gender differences in treatment intensity, including differences in level of care, have been reported. Also differences in benefit from certain treatments, especially invasive treatment, have been discussed. Finally, differences in outcome between men and women have been proposed. Results have been inconsistent, partly depending on if and how adjustment for differences in background characteristics has been made.
  •  
14.
  •  
15.
  •  
16.
  •  
17.
  •  
18.
  •  
19.
  •  
20.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 28

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy